Researchers have discovered that the type 2 drug Avandia improved exercise function in people with type 2 diabetes.
The researchers noted that people with type 2 diabetes have an “impaired ability to carry out maximal exercise” and hypothesized that “administration of a thiazolidinedione (TZD) agent would improve exercise capacity in [cases of] type 2 diabetes.”
Twenty type 2 participants were randomly assigned to receive either 4 milligrams per day of Avandia or a matching placebo. After four months, participants in the Avandia group had improved maximal oxygen consumption, insulin sensitivity and endothelial function. Placebo-treated participants showed no changes in maximal oxygen consumption.
The researchers conclude, “Whether this is due to the observed improvements in insulin sensitivity and/or endothelial function or to another action of the TZD class requires further exploration.”
—Diabetes Care, December 2005